All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How do methylation regulatory gene mutations affect outcome in patients with ELN favorable-risk AML?
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to James Yu, AdventHealth Orlando, Orlando, US. We asked, How do methylation regulatory gene mutations affect outcome in patients with ELN favorable-risk AML?
How do methylation regulatory gene mutations affect outcome in patients with ELN favorable-risk AML?
Yu outlines data observing the effect of methylation regulatory gene mutations (DNMT3A, TET2, IDH1, and IDH2) on survival outcomes in patients with favorable-risk AML according to the 2017 European LeukemiaNet (ELN) classification. He compares these outcomes with those of patients with favorable-risk AML negative for mutations, as well as patients with ELN intermediate- and adverse-risk AML.
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox